The average percentage of CAPS+ cells decreased with increasing tumor grade (40% in benign serous cystadenomas, 31.54% in serous borderline tumors, 18.86% in low-grade serous carcinomas, and 2.7% in HGSOCs (Figure 2A–D and Table 1). The gene discussed is CAPS; the disease is serous adenocarcinoma.